RT Journal Article
T1 A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
A1 Vishwanathan, Karthick
A1 Sanchez-Simon, Inmaculada
A1 Keam, Bhumsuk
A1 Penel, Nicolas
A1 de Miguel-Luken, Maria
A1 Weilert, Doris
A1 Mills, Andrew
A1 Marotti, Marcelo
A1 Johnson, Martin
A1 Ravaud, Alain
K1 epidermal growth factor receptors
K1 kidney
K1 non-small cell lung cancer
K1 osimertinib
K1 pharmacokinetics
K1 renal disposition
K1 tyrosine kinase inhibitors
AB Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. In this phase I study, we assessed the effects of normal renal function (NRF) and severe renal impairment (SRI) on the pharmacokinetics (PK) of osimertinib in patients with solid tumors. Part A: patients with NRF (creatinine clearance [CrCL] ≥90 mL/min), and SRI, (CrCL
YR 2020
FD 2020
LK http://hdl.handle.net/10668/15791
UL http://hdl.handle.net/10668/15791
LA en
DS RISalud
RD Apr 5, 2025